BET-EFF (MV-4-11): Sacrificing 4 Sick Mice – Tumor Burden

Slides:

Advertisements

Similar presentations

Supplementary Figure S1.

Advertisements

Fig. 2. The expression of pKr-2 in the substantia nigra (SN) of patients with Parkinson's disease (PD). (A, B) Western blot analysis for pKr-1-2 and pKr-2,

BET-EFF (MV-4-11): Sacrificing 2 Sick Mice – Tumor Burden

Cantharidin Inhibits the Growth of Triple-Negative Breast Cancer Cells by Suppressing Autophagy and Inducing Apoptosis in Vitro and in.

BM SPL PB Beads & Nucleated HLA-ABC+ Beads & Nucleated HLA-ABC+

Drug concentration (μM)

Selinexor combines with immune checkpoint blockade to slow B16F10 melanoma tumor growth. Selinexor combines with immune checkpoint blockade to slow B16F10.

Anti-CD40 and CpG induce activation of T cells in draining lymph nodes

Volume 21, Issue 12, Pages (December 2017)

Median Tumor Development Time

Drug response in a genetically engineered mouse model of multiple myeloma is predictive of clinical efficacy by Marta Chesi, Geoffrey M. Matthews, Victoria.

A B A B C Supplementary Fig. 8 Supplementary Fig. 9

Fig. 6. AZD6738 induces DNA damage and apoptosis and exhibits antitumor efficacy in xenograft models of high-risk medulloblastoma and neuroblastoma. AZD6738.

Effects of senescent cells on activity.

A B C D E F Supplementary Fig. 1. Gating strategy for CD44+CD133+CD24+ B16 tumor initiating cells (TIC). Cells were gated on CD44. CD44 positive cells.

A B C D E F Supplementary Fig. 2. Gating strategy for CD44+CD24+ ID8agg tumor initiating cells (TIC). Cells were gated on CD44. CD44 positive cells were.

Effects of AG-221 treatment on survival and cell differentiation in an IDH2R140Q primary human AML xenograft model. Effects of AG-221 treatment on survival.

Combined A2A receptor and PD-1 blockade is not effective in IFNγ−/− mice. Combined A2A receptor and PD-1 blockade is not effective in IFNγ−/− mice. AT-3ovadim.

BV6 increases tumor burden in bone.

Figure 2S (Supplementary Data)

DQ661 improves survival in colon cancer model and potentiates activity of gemcitabine in KPC pancreatic cancer syngeneic model. DQ661 improves survival.

Fig. 4. Antitumor efficacy of ERY974 against various cancer types.

Estrogen drives accumulation of myelomonocytic (M-MDSC) and granulocytic (G-MDSC) MDSCs and increases the immunosuppressive potential of G-MDSCs. Estrogen.

Fig. 4. BET inhibition sensitizes HR-proficient tumors to PARPi treatment in vivo. BET inhibition sensitizes HR-proficient tumors to PARPi treatment in.

FK506 Controls CD40L-Induced Systemic Autoimmunity in Mice

Supplementary Figure 1 a b c d e 1 2 cGMP levels (pmol/ml) vehicle

Imetelstat, a telomerase inhibitor, is capable of depleting myelofibrosis stem and progenitor cells by Xiaoli Wang, Cing Siang Hu, Bruce Petersen, Jiajing.

Fig. 7. KIF11 informs patient prognosis, and targeting improves survival in a preclinical model. KIF11 informs patient prognosis, and targeting improves.

Effects of in vivo Nutlin‐3 treatment on CSC content of Numb− and Numb+ tumors Effects of in vivo Nutlin‐3 treatment on CSC content of Numb− and Numb+

Two distinct CXCR4 antagonists mobilize progenitor cells in mice by different mechanisms by Andia N. Redpath, Moïra François, Suet-Ping Wong, Dominique.

CXCR5 expression accelerates Eμ-Tcl1 leukemogenesis and is indispensable for tumor cell recruitment to lymphoid B-cell follicles. CXCR5 expression accelerates.

Histological and mRNA analysis of the inflammatory cytokines in the vehicle‐ or etifoxine‐treated mice at onset of clinical symptoms.A–D.At day 10 p.i.,

CD8+ T cells were immunomodulated and required for the efficacy of anti–4-1BB/anti–PD-1 combination treatment. CD8+ T cells were immunomodulated and required.

Treatment with NVP-AEW541 shows no efficacy in an s. c

Analysis of the Warburg signature.

by Pamela J. Sung, Mayumi Sugita, Holly Koblish, Alexander E

Metformin and rapamycin decreased tumor weights in obese prediabetic mice. Metformin and rapamycin decreased tumor weights in obese prediabetic mice. A:

Diclofenac treatment reduces L-selectin on peripheral blood and infiltrated leukocytes but does not alter accumulation in the injured spinal cord. Diclofenac.

Effect of mitomycin C and bortezomib on the growth of LS174T intraperitoneal tumors. Effect of mitomycin C and bortezomib on the growth of LS174T intraperitoneal.

Fig. 4 Administration of BMS to mice inhibits autoimmune-relevant pharmacodynamic endpoints driven by IL-12 and IFNα. Administration of BMS

Fig. 5 Treatment with BMS (PO BID) protects from wasting and colitis in two SCID mouse models. Treatment with BMS (PO BID) protects from.

TH-302 has antileukemia activity in an in vivo primary AML xenograft murine model. TH-302 has antileukemia activity in an in vivo primary AML xenograft.

E-cadherin synthetic lethal effects operate in vivo in E-cadherin–defective breast tumors. E-cadherin synthetic lethal effects operate in vivo in E-cadherin–defective.

GS87 demonstrates efficacy in a circulating AML mouse model system.

EHop-016 and INK128 treatment of myxofibrosarcoma xenografts in NSG mice. EHop-016 and INK128 treatment of myxofibrosarcoma xenografts in NSG mice. A,

PRIMA-1Met inhibits the growth of multiple myeloma tumors with mutant p53 in vivo. PRIMA-1Met inhibits the growth of multiple myeloma tumors with mutant.

Vascular staining in CWR22R xenograft tumors.

Effect of therapy with S247 on the development of liver metastases after 14 and 21 days of tumor growth. Effect of therapy with S247 on the development.

The antitumor and antimetastatic properties of PF in the MX1 orthotopic model. The antitumor and antimetastatic properties of PF in the.

PVHA increased anti-PD-L1–mediated growth inhibition in 4T1/HAS3 tumors. PVHA increased anti-PD-L1–mediated growth inhibition in 4T1/HAS3 tumors. A, 4T1/HAS3.

Paclitaxel treatment along with CXCR2 knockdown reduces tumor growth and metastasis. Paclitaxel treatment along with CXCR2 knockdown reduces tumor growth.

Antitumor effects of celastrol in vitro and in vivo.

In vivo AraC treatment does not induce any consistent changes in CD34+/−CD38+/− phenotypes nor in quiescent leukemic cells but increases apoptotic cell.

MEDI4736 shows antitumor activity in xenograft mouse models of human cancer. MEDI4736 shows antitumor activity in xenograft mouse models of human cancer.

Combined loss of MPG and ATM sensitizes pGBM cells to temozolomide (TMZ) in vivo. Combined loss of MPG and ATM sensitizes pGBM cells to temozolomide (TMZ)

Pharmacodynamic evaluation of VT-464 and ABI in MR49F xenograft model.

ESKM treatment does not affect leukocyte or HSC counts in HLA-A

Determination of MTD for romidepsin and pralatrexate and associated antitumor activity. Determination of MTD for romidepsin and pralatrexate and associated.

A to C, MetMAb shows strong antitumor activity in the KP4 orthotopic model of pancreatic cancer by ultrasound. A to C, MetMAb shows strong antitumor activity.

Impact of eNOS expression and treatment with GSNO on prostate tumor growth. Impact of eNOS expression and treatment with GSNO on prostate tumor growth.

MGA271 exhibits potent in vivo antitumor activity toward tumor cell carcinoma xenografts. MGA271 exhibits potent in vivo antitumor activity toward tumor.

Treatment with a Ron inhibitor significantly reduces metastatic outgrowth. Treatment with a Ron inhibitor significantly reduces metastatic outgrowth. A,

Complete Vehicle Systems.

Inhibition of spontaneous pulmonary metastasis and prolonged survival after removal of primary tumor and intratracheal delivery of rAAV2/5-VAS. Inhibition.

Cabozantinib causes significant tumor cell elimination in vivo, but modest apoptosis induction in vitro. Cabozantinib causes significant tumor cell elimination.

GCS-100 selectively kills KRAS-addicted lung tumors.

Ex vivo profiling of PD-1 blockade using MDOTS

Inhibition of MCL1 reduces AML in an in vivo murine model.

Bezafibrate increases the number of effector CTLs by enhancing their survival capacity and proliferation. Bezafibrate increases the number of effector.

Parthenolide inhibits tumor promotion and increases p21 expression in vivo. Parthenolide inhibits tumor promotion and increases p21 expression in vivo.

Presentation transcript:

BET-EFF (MV-4-11): Sacrificing 4 Sick Mice – Tumor Burden (5/27/16 – Day 13 of Drug Treatment) Beads & Nucleated Cells – HLA-ABC Staining) PB SPL BM 5175 (20mg/kg I-BET) 5176 (20mg/kg I-BET) 5154 (Vehicle) 5171 (Vehicle)

BET-EFF (MV-4-11): Sacrificing 4 Sick Mice – Tumor Burden (5/27/16 – Day 13 of Drug Treatment) Beads & Nucleated Cells (Isotype Control) PB SPL BM 5175 (20mg/kg I-BET) 5176 (20mg/kg I-BET) 5154 (Vehicle) 5171 (Vehicle)

BET-EFF (MV-4-11): Sacrificing 4 Sick Mice – Tumor Burden (5/27/16 – Day 13 of Drug Treatment) Nucleated Cells  HLA-ABC+ (HLA-ABC Staining) PB SPL BM 5175 (20mg/kg I-BET) 5176 (20mg/kg I-BET) 5154 (Vehicle) 5171 (Vehicle)

BET-EFF (MV-4-11): Sacrificing 4 Sick Mice – Tumor Burden (5/27/16 – Day 13 of Drug Treatment) Nucleated Cells  HLA-ABC+ (Isotype Control) PB SPL BM 5175 (20mg/kg I-BET) 5176 (20mg/kg I-BET) 5154 (Vehicle) 5171 (Vehicle)

BET-EFF (MV-4-11): Sacrificing 4 Sick Mice – Tumor Burden (5/27/16 – Day 13 of Drug Treatment) PI- Live Cells (HLA-ABC Staining) PB SPL BM 5175 (20mg/kg I-BET) 5176 (20mg/kg I-BET) 5154 (Vehicle) 5171 (Vehicle)

BET-EFF (MV-4-11): Sacrificing 4 Sick Mice – Tumor Burden (5/27/16 – Day 13 of Drug Treatment) PI- Live Cells (Isotype Control) PB SPL BM 5175 (20mg/kg I-BET) 5176 (20mg/kg I-BET) 5154 (Vehicle) 5171 (Vehicle)

BET-EFF (MV-4-11): Sacrificing 4 Sick Mice – Tumor Burden (5/27/16 – Day 13 of Drug Treatment) HLA-ABC+ (HLA-ABC Staining) PB SPL BM 5175 (20mg/kg I-BET) 5176 (20mg/kg I-BET) 5154 (Vehicle) 5171 (Vehicle)

BET-EFF (MV-4-11): Sacrificing 4 Sick Mice – Tumor Burden (5/27/16 – Day 13 of Drug Treatment) HLA-ABC+ (Isotype Control) PB SPL BM 5175 (20mg/kg I-BET) 5176 (20mg/kg I-BET) 5154 (Vehicle) 5171 (Vehicle)

BET-EFF (MV-4-11): Sacrificing 4 Sick Mice – Tumor Burden (5/27/16 – Day 13 of Drug Treatment) HLA-ABC+ (HLA-ABC Staining) PB SPL BM 5175 (20mg/kg I-BET) 5176 (20mg/kg I-BET) 5154 (Vehicle) 5171 (Vehicle)

BET-EFF (MV-4-11): Sacrificing 4 Sick Mice – Tumor Burden (5/27/16 – Day 13 of Drug Treatment) HLA-ABC+ (Isotype Control) PB SPL BM 5175 (20mg/kg I-BET) 5176 (20mg/kg I-BET) 5154 (Vehicle) 5171 (Vehicle)

BET-EFF (MV-4-11): Sacrificing 4 Sick Mice – Tumor Burden (5/27/16 – Day 13 of Drug Treatment) HLA-ABC+  Annexin V vs PI (HLA-ABC Staining) PB SPL BM 5175 (20mg/kg I-BET) 5176 (20mg/kg I-BET) 5154 (Vehicle) 5171 (Vehicle)

BET-EFF (MV-4-11): Sacrificing 4 Sick Mice – Tumor Burden (5/27/16 – Day 13 of Drug Treatment) HLA-ABC+  Annexin V vs PI (Isotype Control) PB SPL BM 5175 (20mg/kg I-BET) 5176 (20mg/kg I-BET) 5154 (Vehicle) 5171 (Vehicle)